METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR
申请人:Dousson Cyril B.
公开号:US20120252721A1
公开(公告)日:2012-10-04
Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
申请人:Dousson Cyril B.
公开号:US08362068B2
公开(公告)日:2013-01-29
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
申请人:Idenix Pharmaceuticals LLC
公开号:EP2513113B1
公开(公告)日:2018-08-01
Facile and Scalable Synthesis of the Fused-Ring Heterocycles Thieno[3,2-<i>b</i>]thiophene and Thieno[3,2-<i>b</i>]furan
作者:John T. Henssler、Adam J. Matzger
DOI:10.1021/ol9010745
日期:2009.7.16
An optimized synthetic methodology which allows for efficient and scalable access to the important fused-ring heterocycle thieno[3,2-b]thiophene and the first reported isolation of thieno[3,2-b]furan Is presented. The properties of thieno[3,2-b]furan were assessed through a detailed analysis of the NMR data and an investigation of the chemical reactivity. Thieno[3,2-b]furan is chemically robust and offers good selectivity toward functionalization at the 2-position via bromination and the 5-position via deprotonation.